Description
Pharmacologie
12.1 Mecanisme d action (CDK) 4 6 D1 CDK4/6 , G1 S , (ER) , (Rb) , E2F ,
Posologie
2.1 IBRANCE 125 mg , 21 , 7 , 28 IBRANCE [ (12.3)] IBRANCE , IBRANCE , 500 mg, 1 15 29 ,
Precautions
5.1 PALOMA-2 , , 80% PALOMA-3 , 83% PALOMA-2 , IBRANCE 66% ≥3 PALOMA-3 , IBRANCE 66% ≥3 PALOMA-2 PALOMA-3 , 15 ,≥3 7 [ (6.1)] IBRANCE 15 , 3 4 , [ 2.2 ]
Interactions médicamenteuses
CYP3A SULT SULT2A1 , CYP3A 7.1 CYP3A , CYP3A 87% CYP3A , /
Effets indésirables
Description • [ Precautions(5.1)] • / [ Precautions(5.2)] 6.1 , , PALOMA-2 IBRANCE (ER) HER2 IBRANCE (125 mg/ ) (2.5 mg/ )
Conservation
IBRANCE IBRANCE (mg) NDC Description 21 / 125 NDC 0069-0189-21 ,0 , , “Pfizer” , “PBC 125” 21 / 100 NDC 0069-0188-21 ,1 ,




